BACKGROUND: Phenethyl isothiocyanate (PEITC) is a natural plant compound with chemopreventative potential against some cancers and the ability to induce apoptosis in breast cancer cells. METHODS: Female mouse mammary tumor virus-neu mice were fed a control AIN-76A diet (n = 35) or the same diet supplemented with 3 µmol PEITC/g diet (n = 33) for 29 weeks, at which time they were killed. Breast tissue sections were stained with hematoxylin and eosin for histopathological assessments, and incidence and size of macroscopic mammary tumors were assessed. Cell proliferation (Ki-67 staining), apoptosis (terminal deoxynucleotidyl transferase-mediated dUTP nick-labeling), and neoangiogenesis (CD31 staining) were determined in tumor sections. Plasma levels of transthyretin were measured in treated and control mice. Expression of proteins in mammary tumor sections was determined by immunohistochemistry. Proteomic profiling was performed by two-dimensional gel electrophoresis followed by mass spectrometry. All statistical tests were two-sided. RESULTS: Administration of PEITC for 29 weeks was associated with 53.13% decreased incidence of macroscopic mammary tumors (mean tumor incidence, PEITC-supplemented diet vs control diet, 18.75% vs 40.00%, difference = -21.25%, 95% confidence interval [CI] = -43.19% to 0.69%, P = .07) and with a 56.25% reduction in microscopic mammary carcinoma lesions greater than 2 mm(2) (mean incidence, PEITC-supplemented diet vs control diet, 18.75% vs 42.86%, difference = -24.11%, 95% CI = -46.35% to -1.86%, P = .04). PEITC-mediated mammary cancer growth inhibition was not because of suppression of human epidermal growth factor receptor-2 expression but was associated with reduced cellular proliferation and neoangiogenesis, increased apoptosis, and altered expression of several proteins, including decreased ATP synthase in the tumor and increased plasma levels of transthyretin. CONCLUSIONS: PEITC inhibits the growth of mammary cancers in a mouse model with similarities to human breast cancer progression. ATP synthase and transthyretin appear to be novel biomarkers associated with PEITC exposure.
BACKGROUND:Phenethyl isothiocyanate (PEITC) is a natural plant compound with chemopreventative potential against some cancers and the ability to induce apoptosis in breast cancer cells. METHODS: Female mouse mammary tumor virus-neu mice were fed a control AIN-76A diet (n = 35) or the same diet supplemented with 3 µmol PEITC/g diet (n = 33) for 29 weeks, at which time they were killed. Breast tissue sections were stained with hematoxylin and eosin for histopathological assessments, and incidence and size of macroscopic mammary tumors were assessed. Cell proliferation (Ki-67 staining), apoptosis (terminal deoxynucleotidyl transferase-mediated dUTP nick-labeling), and neoangiogenesis (CD31 staining) were determined in tumor sections. Plasma levels of transthyretin were measured in treated and control mice. Expression of proteins in mammary tumor sections was determined by immunohistochemistry. Proteomic profiling was performed by two-dimensional gel electrophoresis followed by mass spectrometry. All statistical tests were two-sided. RESULTS: Administration of PEITC for 29 weeks was associated with 53.13% decreased incidence of macroscopic mammary tumors (mean tumor incidence, PEITC-supplemented diet vs control diet, 18.75% vs 40.00%, difference = -21.25%, 95% confidence interval [CI] = -43.19% to 0.69%, P = .07) and with a 56.25% reduction in microscopic mammary carcinoma lesions greater than 2 mm(2) (mean incidence, PEITC-supplemented diet vs control diet, 18.75% vs 42.86%, difference = -24.11%, 95% CI = -46.35% to -1.86%, P = .04). PEITC-mediated mammary cancer growth inhibition was not because of suppression of humanepidermal growth factor receptor-2 expression but was associated with reduced cellular proliferation and neoangiogenesis, increased apoptosis, and altered expression of several proteins, including decreased ATP synthase in the tumor and increased plasma levels of transthyretin. CONCLUSIONS:PEITC inhibits the growth of mammary cancers in a mouse model with similarities to humanbreast cancer progression. ATP synthase and transthyretin appear to be novel biomarkers associated with PEITC exposure.
Authors: J A Cauley; L Norton; M E Lippman; S Eckert; K A Krueger; D W Purdie; J Farrerons; A Karasik; D Mellstrom; K W Ng; J J Stepan; T J Powles; M Morrow; A Costa; S L Silfen; E L Walls; H Schmitt; D B Muchmore; V C Jordan; L G Ste-Marie Journal: Breast Cancer Res Treat Date: 2001-01 Impact factor: 4.872
Authors: Uwe Zimmermann; Stefan Balabanov; Jürgen Giebel; Steffen Teller; Heike Junker; Dieter Schmoll; Chris Protzel; Christian Scharf; Britta Kleist; Reinhard Walther Journal: Cancer Lett Date: 2004-06-08 Impact factor: 8.679
Authors: Suman K Samanta; Anuradha Sehrawat; Su-Hyeong Kim; Eun-Ryeong Hahm; Yongli Shuai; Ruchi Roy; Subrata K Pore; Krishna B Singh; Susan M Christner; Jan H Beumer; Nancy E Davidson; Shivendra V Singh Journal: J Natl Cancer Inst Date: 2016-12-31 Impact factor: 13.506
Authors: Su-Hyeong Kim; Eun-Ryeong Hahm; Julie A Arlotti; Suman K Samanta; Michelle B Moura; Stephen H Thorne; Yongli Shuai; Carolyn J Anderson; Alexander G White; Anna Lokshin; Joomin Lee; Shivendra V Singh Journal: Breast Cancer Res Treat Date: 2016-04-21 Impact factor: 4.872